Impact BioMedical, Inc. (IBO) AI Stock Analysis

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. Its offerings include Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds for oncology, inflammatory disorders, and neurology, and Laetose technology derived from sugar and inositol to inhibit inflammatory and metabolic responses. The company also develops functional fragrance formulation, or 3F, for antimicrobial and repellent applications, and Equivir/Equivir G polyphenol blends with antiviral properties. Impact BioMedical operates as a subsidiary of DSS BioHealth Security, Inc.

Impact BioMedical's revenue grew from $50,000 in FY2021 and $50,000 in FY2022 to $1.0M in FY2023, representing 1960.0% growth. Revenue reached $1.6M in FY2024, up 57.3%, before declining 98.0% to $32,000 in FY2025. Over the 4-year period from FY2021 to FY2025, revenue compound annual growth rate was -10.6%. Operating margin moved from -6808.0% in FY2021 to -1775.1% in FY2024 and -13343.8% in FY2025, while net margin was -36993.8% in FY2025 with net income of -$11.8M. For the trailing twelve months, revenue was $35,000, and quarterly revenue growth yoy fell 57.1% as of the latest quarter on June 30, 2026.

As of June 30, 2026, Impact BioMedical held cash and short-term investments of $10,000 against total assets of $16.7M and shareholders' equity of $10.8M. Its current ratio stood at 0.16. For FY2025, operating cash flow was -$1.9M and free cash flow was -$1.9M, following free cash flow of -$5.6M in FY2024. In FY2025, research and development expense was $340,000. Over a 5-year period, share count changed by 837.2%.

Impact BioMedical has a market cap of $22.9M and an enterprise value of $79.6M. The stock trades at a price-to-sales multiple of 654.2x, significantly higher than the 4.1x median of its US-listed Healthcare peers. Its ev_to_ebitda stands at 4.7x compared to the peer median of 12.0x, while trailing price-to-earnings is 0.3x versus the peer median of 24.6x. Over the past year, the stock generated a return of -64.7%, trailing the S&P 500 return of 16.8%.

Impact BioMedical currently has no analyst rating counts, price targets, or consensus recommendations recorded. The company's next earnings date is scheduled for November 6, 2026. The business reported diluted eps of -$0.78 in FY2025, compared to eps of $2.30 in FY2024 and trailing twelve month eps of $9.50 as of June 30, 2026. Investors will track upcoming operational disclosures on November 6, 2026.

This page is an AI-written research summary of Impact BioMedical, Inc. (IBO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IBO income statement, IBO balance sheet, IBO key metrics, IBO chart. See the IBO stock overview for the latest quote and news.